Find clinical trials for Adenocarcinoma in St Louis, MO

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Carcinoma

Cancer

Pancreatic Cancer

Stomach Cancer

Colorectal Cancer

Prostatic Cancer

Esophageal Cancer

Adenocarcinoma trials near St Louis, MO, USA:

Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma

Patients with advanced pancreas adenocarcinoma will be randomized on a 6:1 basis to receive standard of care chemotherapy followed by adapti...

Enrolling

Pancreas Adenocarcinoma

Pancreas Cancer

Procedure: Tumor biopsy

Device: Adaptive stereotactic body radiation therapy

Phase 2

The Washington University

Saint Louis, Missouri, United States

BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

The purpose of this research study is to learn more about a new combination of drugs being given to treat pancreatic cancer. The drugs being tested a...

Active, not recruiting

Pancreatic Ductal Adenocarcinoma

Drug: BMS-813160

Drug: Gemcitabine

Phase 1, Phase 2

The Washington University

Saint Louis, Missouri, United States

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201)

This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7...

Active, not recruiting

Pancreatic Ductal Adenocarcinoma

NRAS G12D

Drug: ELI-002 2P

Phase 1

Elicio Therapeutics

Saint Louis, Missouri, United States and 9 other locations

A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall surviv...

Active, not recruiting

Metastatic Pancreatic Adenocarcinoma

Metastatic Pancreatic Cancer

Drug: gemcitabine

Drug: nab-paclitaxel

Phase 2

Astellas

Creve Coeur, Missouri, United States and 137 other locations

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma...

Enrolling

Gastroesophageal Junction Cancer

Gastric Cancer

Drug: Apatinib

Drug: Ramucirumab+ paclitaxel

Phase 3

AstraZeneca

Saint Louis, Missouri, United States and 118 other locations

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trast...

Active, not recruiting

Gastroesophageal Junction Adenocarcinoma

Gastric Neoplasms

Drug: Oxaliplatin

Drug: Cisplatin

Phase 3

Merck Sharp & Dohme (MSD)

Saint Louis, Missouri, United States and 191 other locations

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared...

Active, not recruiting

Advanced/Metastatic Gastroesophageal Adenocarcinoma

Drug: Oxaliplatin

Biological: Lenvatinib

Phase 3

Merck Sharp & Dohme (MSD)

Saint Louis, Missouri, United States and 176 other locations

Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC (ESOGUARDBE2)

Barrett's Esophagus (BE), with or without dysplasia, and esophageal adenocarcinoma (EAC) as compared to Esophagogastroduodenoscopy (EGD) plu...

Enrolling

Esophageal Adenocarcinoma

Barretts Esophagus With Dysplasia

Diagnostic Test: Esophagogastroduodenoscopy

Device: EsoGuard (lab assay)

Lucid Diagnostics

Saint Louis, Missouri, United States and 37 other locations

Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer (RAMP205)

and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma...

Enrolling

Metastatic Cancer

KRAS Activating Mutation

Drug: avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel

Phase 1, Phase 2

Verastem

Saint Louis, Missouri, United States and 10 other locations

Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)

This is a randomized phase II study examining nivolumab alone versus radiation therapy with nivolumab in subjects who did not have disease progressio...

Active, not recruiting

Gastroesophageal Adenocarcinoma

Drug: Nivolumab 240 MG

Phase 2

Weill Cornell Medicine (WCM)

Saint Louis, Missouri, United States and 4 other locations

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms

Find clinical trials for Adenocarcinoma in .css-epvm6{white-space:nowrap;}St Louis, MO

Related conditions:

Adenocarcinoma trials near St Louis, MO, USA:

Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma

BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201)

A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC (ESOGUARDBE2)

Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer (RAMP205)

Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)

Find clinical trials for Adenocarcinoma in St Louis, MO